Papers/PMID:37037891
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.
Scientific reports2023The record
10 findings drawn from this paper, on 1 compound across 10 endpoints, 6 of them null.
What it reported
How to read these marksWhat moved
4 findings
curcumin — decreases body mass index
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×2“Thirteen studies assessed reduction of BMI indicating curcumin supplementation was effective in lowering BMI with MD (95% CI) of −0.34 (−0.62, −0.05) kg/m2; I2 = 62.7%, see Supplementary Appendix Q.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 13 RCTs; BMI was an additional (secondary) outcome of this review
Effect -0.34 mean difference, 95% CI -0.62 to -0.05
curcumin — decreases alanine aminotransferase
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×2“The overall pooling indicated that curcumin supplementation was significantly associated with reduced ALT [MD (95% CI) of −5.61 (−9.37, −1.85) units/L] with moderate heterogeneity observed (I2 = 64.3%).”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); overall pooling of 14 RCTs, all curcumin forms; liver enzymes were a primary outcome of interest
Effect -5.61 mean difference, 95% CI -9.37 to -1.85
curcumin — decreases fasting blood glucose
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“Twelve studies assessed reduction of FBS indicating curcumin supplementation was associated with a significant reduction in FBS, with MD (95% CI) of −2.05 (−3.08, −1.01) mg/dL, I2 = 0%, see Supplementary Appendix O.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 12 RCTs; glycaemic indices were an additional (secondary) outcome of this review, not a liver endpoint
Effect -2.05 mean difference, 95% CI -3.08 to -1.01
curcumin — decreases aspartate aminotransferase
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×2“The overall pooling of data indicated that curcumin supplementation was significantly associated with reduced AST with MD (95% CI) of −3.90 (−5.97, −1.82) units/L, although high heterogeneity was observed (I2 = 73.9%).”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); overall pooling of 15 RCTs, all curcumin forms; liver enzymes were a primary outcome of interest
Effect -3.9 mean difference, 95% CI -5.97 to -1.82
What did not
6 findings
curcumin — no detected effect on diastolic blood pressure (setting unspecified)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×1“Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate
Effect -0.02 mean difference, 95% CI -0.55 to 0.52
curcumin — no detected effect on serum alkaline phosphatase
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×3“There was no significant association between curcumin supplement and ALP [MD (95% CI) of −8.88 (−24.68, 6.93) units/L].”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 6 RCTs, all using bioavailability-enhanced curcumin forms; liver enzymes were a primary outcome of interest
Effect -8.88 mean difference, 95% CI -24.68 to 6.93
curcumin — no detected effect on systolic blood pressure (setting unspecified)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×1“Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate
Effect -0.29 mean difference, 95% CI -0.91 to 0.34
curcumin — no detected effect on glycated haemoglobin (HbA1c)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×1“However, curcumin was not significantly associated with HbA1c based on pooling three included studies with MD (95% CI) of −0.24 (−0.66, 0.18) %, I2 = 85.8%, see Supplementary Appendix P.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 3 RCTs pooled; glycaemic indices were an additional (secondary) outcome of this review
Effect -0.24 mean difference, 95% CI -0.66 to 0.18
curcumin — no detected effect on LDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“However, the pooled effects of curcumin supplementation on LDL, HDL, and TG were not statistically significant regardless of its forms, see Supplementary Appendix S–U.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD/NASH); additional (non-liver-enzyme) outcome of the updated meta-analysis, pooled across 11 trials
curcumin — no detected effect on HDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×1“However, the pooled effects of curcumin supplementation on LDL, HDL, and TG were not statistically significant regardless of its forms, see Supplementary Appendix S–U.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD/NASH); additional (non-liver-enzyme) outcome of the updated meta-analysis, pooled across 10 trials